Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes

Ofri Mosenzon*, Meir Schechter, Gil Leibowitz

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    6 Scopus citations


    Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are highly effective in reducing glycemia in patients with type 2 diabetes (T2D). These medications effectively reduce cardiovascular (CV) risk in patients with T2D and established CV disease or with multiple risk factors. In addition, treatment with GLP-1 RA may exert protective effects on the diabetic kidney. Herein, we summarize the findings regarding the kidney safety and efficacy of GLP-1 RAs in patients with T2D. We review data from GLP-1 RAs phase 3 kidney studies, CV outcome trials, as well as real-world evidence. The accumulating data show that treatment with GLP-1 RAs is safe, well-tolerated, and effective in patients with different levels of kidney dysfunction. Furthermore, CV outcome trials suggest that GLP-1 RAs reduce albuminuria and may attenuate the decline in kidney function over time. The ongoing FLOW trial studying the effects of semaglutide in patients with diabetic kidney disease is expected to shed light on the effects of GLP-1 RAs on kidney outcomes and clarify their role in the management of patients with T2D and kidney disease.

    Original languageAmerican English
    Pages (from-to)347-360
    Number of pages14
    JournalAdvances in Chronic Kidney Disease
    Issue number4
    StatePublished - Jul 2021

    Bibliographical note

    Publisher Copyright:
    © 2021 The Authors


    • Albuminuria
    • Diabetic kidney disease
    • GLP-1 RAs
    • Kidney outcome trials
    • Type 2 diabetes


    Dive into the research topics of 'Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes'. Together they form a unique fingerprint.

    Cite this